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Ethnopharmacological relevance: Casearia sylvestris S.w (Salicaceae) is catalogued by the Brazilian Uniﬁed
Health System as a plant of interest for the Brazilian population with the purpose of treating in-
ﬂammatory disorders, such as pain and gastrointestinal disorders based on the folk use and some lit-
erature about efﬁcacy; however, no toxicological studies concerned the safety of extract ﬂuid of this plant
have been reported.
Aim of the study: The present study was carried out to evaluate the acute and subchronic toxicity of the
hydroethanolic extract ﬂuid (FE) obtained from leaves of C. sylvestris in Wistar rats.
Materials and methods: In the acute toxicity test three female Wistar rats were treated with a single dose
of FE (2000 mg/kg) administered by oral gavage and observed for 14 days in order to identify signs of
toxicity or death. In subchronic toxicity study animals received, by daily gavage three doses 60, 120 and
240 mg/kg of the FE of the plant for 28 and 90 days. The animals were observed daily for clinical signs
and mortality. Body weight and food consumption were measured weekly and at the end of treatment
were analysed hematological, biochemical and histopathological parameters. Also was analysed the
cellularity of bone marrow and spleen. Moreover, phytochemical analysis by HPLC–PDA–ESIþ/MS and
CG/MS/EI was carried out to qualify the constituents of the extract.
Results: The results of acute study indicated that the LD50 is higher than 2000 mg/kg and at 28 and 90
day oral toxicity showed that there were no toxic effects detected in any of the parameters evaluated:
body weight and relative organ weight, general behavioral changes, haematological and biochemical
parameters and histopathological examination. The analysis by HPLC–PDA–ESIþ/MS and CG/MS/EI
identiﬁed the ﬂavonoids rutin, quercetin and luteolin and also chlorogenic on the extract.
Conclusion: Based on this study the hydroethanolic ﬂuid extract of C. sylvestris could be safe even when
used over a long period for therapeutic uses proposed by the Brazilian Uniﬁed Health System.
& 2015 Elsevier Ireland Ltd. All rights reserved.1. Introduction
In Brazil the use of medicinal plants has an important role in
primary health care, mainly in the communities without easily
access to medicines. Since 2006, the Brazilian government deﬁned
national policies on the use of herbal medicines in The National
Policy of Integrative and Complementary Practices (PNPIC) and
The National Policy of Medicinal Plants and Herbal Medicines
(PNPMF). These documents encourage research into and the de-
velopment of herbal medicines while prioritizing the protection of
biodiversity and promoting greater access to safe and effective
treatments (Carvalho et al., 2011). Furthermore, these documentsrved.
.have led to the inclusion of the use of medicinal plants into the
public health system. Currently, 47 medicinal plants are approved
to be prescribed in the Brazilian Uniﬁed Health System (SUS)
based on ethnopharmacology data (ANVISA, 2011). However,
while there is a widespread use of herbal medicine, little has been
done to establish its safety (Carvalho et al., 2009). In this manner,
although in Brazil, the National Health Surveillance Agency (AN-
VISA) is developing standards for the regulation for the pharma-
ceutical companies submit data on efﬁcacy and safety of herbal
medicines, presently, information and reliable data are scarce and
often contradictory. Thus, it should be considerate that there is a
lack of minimum information necessary for the correct use of
medicinal plants and herbal medicine, which makes an easy target
for self-medication without liability and also it is necessary to
develop protocols of studies and better evaluate the safety of
natural products and herbal medicines, thereby providing a
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In this context, our research group performed a toxicity study
about Casearia sylvestris, which is catalogued by the SUS as a plant
of interest for the Brazilian population with the purpose of treating
inﬂammatory disorders, such as pain and gastrointestinal dis-
orders, such as gastritis and ulcers. In addition, it is used as a ci-
catrizing agent in skin diseases, with its only restriction being
against use during pregnancy, according to the “Formulário de
Fitoterápicos da Farmacopéia Brasileira” (ANVISA, 2011). Moreover,
there are studies showing different uses of it as an antimicrobial
(Da Silva et al., 2008), analgesic and anti-inﬂammatory (Ruppelt
et al., 1991), antivenom (Cavalcante et al., 2007; Cintra-Fran-
cischinelli et al., 2008), cytotoxic effects against tumor cells (Ito-
kawa et al., 1990; Morita et al., 1991; Oberlies et al., 2002) and
gastric antiulcer activities (Basile et al., 1990; Sertié et al., 2000).
Despite the widespread use of C. sylvestris, controlled clinical
studies have not been conducted and there are paucity of data
related to the evaluation of the toxicity of this plant. Therefore, the
aim this study was to evaluate the possible toxic effects of the ﬂuid
extract of C. sylvestris (FE) on preclinical studies, in Wistar male
rats, as acute oral toxicity and repeated dose 28 and 90 day oral
toxicity based on the “Guide to studies of pre-clinical toxicity of
herbal medicines” edited by ANVISA (2004).2. Material and methods
2.1. Plant material
Fresh leaves of C. sylvestris Sw (Salicaceae) were collected at the
University of São Paulo (Parque Esporte para Todos), São Paulo, SP,
Brazil, in February 2009. A voucher herbarium specimen was de-
posited at the Botanic Institute of São Paulo/SP, under reference
number 430190.
The leaves of C. sylvestriswere dried at room temperature. Next,
this material was powdered, and the hydroethanolic ﬂuid extract
extract (FE) was obtained by percolation, following Brazilian Ofﬁ-
cial Pharmacopeia 1st edition instructions. The all material for the
study was prepared in one batch lyophilized and kept frozen at
20 °C until use and was resuspended in distilled water at dif-
ferent doses immediately before administration.
2.2. Phytochemicals analysis
2.2.1. HPLC–PDA–ESIþ /MS analysis
The spectrometric analysis was performed using a Shimadzu©
HPLC system consisting of a LC-10 pump and a SPD-M10A PDA
detector coupled to an ESI/MS. All experiments were carried out in
positive ion mode with a mass spectrometer Esquire 3000 Ion trap
(Bruker Daltonics©, Billerica, MA, USA). PDA signal was acquired
scanning wavelengths between 190 e 800 nm while total ion
chromatogram (TIC) mode was employed for MS analysis. Analysis
of extracts by analytical HPLC was performed using a Varian Pur-
suit C18 column (1504.6 mm i.d.; 5 Vm) maintained at 25 °C.
Solvent system: A: 0.1% acetic acid, B: acetonitrile (HPLC gradua-
tion). A gradient was performed as following: 0' [5]; 0'–15' [28];
15'–55' [68]; 55'–60' [100]; in a ﬂow rate of 1 mL/min. Injection
volume of 20 VL of a sample concentration of 1 mg/mL in H2O.
ESI–MS conditions: positive ion mode scan range: 50–1000 m/z;
Nebulizer gas (N2) 27 psi; dry gas (N2) 7 ml/min; dry temperature
32 °C and HV capillary 4000 V.
2.2.2. GC/MS/EI analysis
The C. sylvestris extract and authentic standards of rutin, quercetin
and chlorogenic acid (Sigma-Aldrichs) were derivatized with N,O-bis
(trimethylsilyl)triﬂuoroacetamide and 1% trimethylchlorosilane (BSTFA/TMCS), and the analysis was performed using an Agilent GC 6890 gas
chromatograph coupled to an Agilent MSD 5973N mass spectrometer
column (HP5 30m, 0.25mm, 0.25 Vm), which was operated in the
electronic impact (EI) mode (70 eV). The temperatures of the injector
and detector ports were kept at 230 °C and 250 °C, respectively, and
the ion sourcewas kept at 200 °C. Heliumwas used as the carrier gas at
a ﬂow rate of 1.0 ml/min. The analysis was performed using the fol-
lowing program: 5min isothermal heating (70 °C), a gradient of 5 °C/
min to 310 °C, and a ﬁnal minute of heating at 310 °C. The temperature
was then equilibrated before automatic injection of the next sample.
The mass spectra were recorded at 2 scans/s with a scanning range of
50–650m/z. Data from chromatograms and mass spectra were ana-
lyzed using the program ChemStation (Agilents) and compared with
the literature (NIST and WILEY 275 L libraries) and data obtained from
authentic standards.
2.3. Animals
Eight three Male and female Wistar rats, 60 days years old, bred
in the Department of Pathology at the School of Veterinary Med-
icine and Animal Sciences, University of São Paulo, were used. The
rats were randomly assigned to the control and treatment groups,
individually housed, maintained under controlled temperature
conditions (22–25 °C), relative humidity (50–65%) and lighting
(12 h/12 h light/dark cycle). Before the test was conducted, the
animals were kept in their cages ﬁve days to allow for acclimati-
zation to the laboratory conditions. Drinking water and standard
diet (Nuvilab-CR1s, Nuvital Nutrientes LTDA) were provided ad
libitum. All procedures were performed following the Guide for the
Care and Use of Laboratory Animals, NIH publication n°85–23 and
were reviewed and approved by the Bioethics Committee of the
FMVZ-USP (process n°1738/09).
2.4. Acute toxicity study
The single-dose acute oral toxicity test was performed ac-
cording to OECD Guideline 423 (OECD, 2001).
Three female Wistar rats were treated with a single dose of FE
(2000 mg/kg) administered by oral gavage. Next, the rats were
closely observed during the ﬁrst day, hourly, and once daily
thereafter for a total of 14 days in order to identify signs of toxicity
or death. The body weight and food consumption of each rat were
measured every 3 days throughout the observation period. At the
end of this period, all survivors were killed to examine macro-
scopic alterations in their vital organs.
2.5. Subchronic 28 and 90 day toxicity studies
In the present study, the doses used were determinate from the
lowest dose (60 mg/kg) with which the extract presented phar-
macological activities (antiulcer activity) in rats (Basile et al.,
1990), and from this dose, applied a factor of 2 and 4 times the
therapeutic dose to established the medium and high doses.
For each experiment, forty male Wistar rats were randomly
allocated into four groups (n¼10) and daily treated, for 28 or 90
days, by oral gavage, the following doses of FE: 0 mg/kg (Co),
60 mg/kg (FE 60), 120 mg/kg (FE 120) and 240 mg/kg (FE 240).
The animals were observed daily for clinical signs and mor-
tality. Body weight and food consumption were measured weekly
throughout the study period. At the end of treatment, all rats were
anesthetized intraperitoneally (ip) with ketamine (50 mg/kg) and
xylazine (5 mg/kg) to collect blood samples by cardiac puncture.
Vacutainers containing EDTA and vacutainers that were dry were
used to process blood for complete blood count (CBC) and serum
biochemistry, respectively. Next, liver, spleen and thymus were
harvested and weighed so that relative weight could be calculated
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from each rat was collected, to verify bone marrow cellularity as
well as from as well spleen.
2.5.1. Complete blood count
The complete blood count was performed using an automated
hematology analyzer Vet ABCTM Animal Blood Counter (Horiba,
ABX Diagnostics). Hematological evaluations included red blood
cell count (RBC), hemoglobin concentration (HGB), hematocrit
(HCT), mean corpuscular volume (MCV), mean corpuscular he-
moglobin (MCH), mean corpuscular hemoglobin concentration
(MCHC), red cell volume distribution (RDW), blood platelet count
(PLT) and white blood cell count (WBC).
2.5.2. Serum biochemistry
Blood samples collected without anticoagulant were allowed to
stand for 45 min at room temperature before being centrifuged at
4000 rpm for 10 min. The serum from each sample was recovered
and placed at 20 °C until required.
Creatinine, urea, uric acid, chloride, total proteins, albumin,
glucose, triglycerides, total cholesterol, aspartate aminotransferase
(AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP)
and gamma glutamyl transferase (GGT) were evaluated using an
automatic chemistry analyzer CELM SBA-200 (Cia. Equipadora de
Laboratórios Modernos, S.A., Brasil).
2.5.3. Histopathology
Histopathological analyses were performed on several organs:
liver, spleen, thymus and kidney. They were ﬁxed in 10% neutral
formalin and routinely processed for parafﬁn embedding. Sections
(5 mm thick) were prepared and stained with hematoxylin and
eosin (HE).
2.6. Statistical analysis
The data were analyzed using GraphPad Prism 4.00s software
(GraphPad Software, Inc., San Diego, CA). Homogeneity of variance
was tested with Barlett's test. If variance was homogeneous, the
data were subjected to one-way analysis of variance (ANOVA)
followed by Dunnett's test for multiple comparisons, otherwise,
data were analyzed by the Kruskal–Wallis nonparametric ANOVA
followed by Dunn's test. All data were expressed as the mean7SD,
and differences were considered to be statistically signiﬁcant at
po0.05.3. Results and discussion
3.1. Phytochemical analysis
Data analysis by HPLC-PDA-ESI/MSþ system of chromatogram
proﬁle of C. sylvestris extract at 254 nm, which showed 18 chro-
matographic peaks with respective retention time (Rt). The total
ion currents (TIC) of FA components and the positive ion ESI
spectrum of rutin showed an abundant [Mþ H]þ ion peak at m/z
611 (M¼610, C27H30O6), ion peak at m/z 303.0 corresponding to
quercetin [MþH]þ , the aglycone moiety of rutin and the peak at
m/z 465 resulted from loss of rhamnose from rutin similar of
standard at Rt¼26.1 min. The positive ion ESI spectrum of
chlorogenic acid at Rt¼16.3 min was identiﬁed by mass spectrum
data with fragment ions m/z 355 [MþH]þ (M¼354, C16H18O9)
and m/z 163 (100%) [MC9H7O3]. The luteolin glucoside was
identiﬁed at Rt¼33.7 min; m/z¼645, 639, 286 [luteolin aglycone
MþHþ , M¼286, C15H10O6]. Data analysis by GC/MS/EI after de-
rivatization identiﬁed the quercetin at Rt¼49.646 min, m/z¼575
(%) e 487 and rutin Rt¼49.486, m/z¼543, 207, 133(90%), 73(100 %)which data were similar of authentic standards.
These ﬂavonoids have been reported to act in the gastro-
intestinal tract showing cytoprotective anti-ulcerogenic efﬁcacy
and antispasmodic, antidiarrheal, antioxidant and antiinﬂamatory
properties (Borrelli and Izzo, 2000; Di Carlo et al., 1999; Havsteen,
2002; La Casa et al., 2000) suggesting they could be correlate with
medicinal activity proposed to this plant. Furthermore, studies
about C. sylvestris also showed the presence of phenolic com-
pounds, mainly ﬂavonoids with rutin in constitution, which can be
pointed as chemical markers (Silva et al., 2006).
Future studies will be conducted in order to verify if ﬂavonoids
found in plant are the main responsible for the gastroprotective e/
or anti-inﬂammatory effects and to standardization this extract.
3.2. Acute toxicity study
The acute toxicity results, with the limit test single dose of
2000 mg/kg of the C. sylvestris extract, in the present study did not
show any signs of toxicity. All rats treated with the FE survived on
the 14-day observation period. No adverse clinical signs were
observed. Body weight and food consumption measurements did
not reveal any difference, and no alterations were observed at
necropsy.
Taking into account that the Globally Harmonized System of
Classiﬁcation and Labelling of Chemicals (GHS) assumes that
substances with values higher than 2000 mg/kg are classiﬁed as
having relatively low acute toxicity, we can consider C. sylvestris FE
safe. Similarly, the low toxicity of C. sylvestris had already been
described by Basile et al. (1990), which showed that the LD 50 was
higher than 1840 mg/kg.
3.3. Subchronic 28 and 90 day toxicity studies
C. sylvestris has been prescribed by SUS to treat gastrointestinal
disorders; therefore, we established the initial dose for the sub-
chronic studies based on the Basile et al. (1990) study that showed
that the antiulcerogenic effective dose is 57.5 mg/kg.
The studies with doses of 60, 120 and 240 mg/kg/day of ﬂuid
extract C. sylvestris for 28 and 90 days show that the treated rats
presented no signs of behavioral changes or clinical toxic signs, as
indicated by the lack of alterations in body weight (P40.05) and
food consumption (P40.05) (Fig. 1), hematological (P40.05)
(Table 1) relative organ weight (P40.05) (Table 2), and histo-
pathological parameters compared to control animals.
On the other hand, some alterations were observed in the
biochemical values in rats treated with 120 and 240 mg/kg C.
sylvestris extract, treated for 28 days as an increase in total pro-
teins (Po0.01 post test Dunnet) and albumin (Po0.05 post test
Dunn's) and decrease in triglyceride (Po0.01 post test Dunnet)
creatinine (Po0.05 post test Dunn's) and chloride levels (Po0.01
post test Dunnet) (Table 3). Rats treated with 240 mg/kg C. syl-
vestris extract for 90 days showed signiﬁcant reductions in crea-
tinine (Po0.05 post test Dunn's) and total cholesterol (Po0.01
post test Dunnet) while animals treated with 120 mg/kg showed
signiﬁcant reductions in total cholesterol and increases in chloride
levels (Table 4).
The result of decrease in triglyceride levels corroborates with a
study conducted by Werle et al. (2009) which showed that the
hydroalcoholic extract of C. sylvestris at 500 mg/kg lowers blood
triglyceride levels, and can indicate this plant as a candidate to a
natural trygliceride reducer. At the same way, the results suggest
that this extract could be a reductor of cholesterol and creatinine.
However, futures experiments should be conducted to better
evaluate this possibility.
In the same manner, although biochemical analysis of serum
collected showed ﬂuctuations of multiple parameters in those











































































Fig. 1. Body weight and food consumption for the rats treated with C. sylvestris hydroethanolic extract: 0 (Co), 60 (FE 60), 120 (FE 120) and 240 (FE 240) mg/kg for 28 days (A
and B) and for 90 days (C and D). No statistical differences were detected between the treated 60, 120 and 240 EF and control groups (n¼10) at every treatment.
Table 1
Complete blood count of rats treated daily, for 28 and 90 days, with C. sylvestris
hydroethanolic extract: 0 (Co), 60 (FE 60), 120 (FE 120) and 240 (FE 240) mg/kg.
28 DAYS
Co FE60 FE120 FE240
HCT (%) 41.073.1 40.872.7 40.571.4 41.773.0
HGB (g/dl) 14.470.7 14.570.6 14.370.6 14.970.5
RBC (106/mm3) 8.370.6 8.270.5 8.370.4 8.570.5
WBC (103/mm3) 5.971.0 5.671.0 5.670.9 5.171.0
PLT (103/mm3) 648.1756.9 649.0764.6 637.9765.0 612.1777.7
MCV (fm3) 48.873.5 50.071.7 48.871.5 48.871.3
MCH (pg) 17.470.8 17.870.8 17.270.5 17.470.7
MCHC (g/dl) 34.871.7 35.671.6 35.471.4 35.871.9
90 DAYS
Co FE60 FE120 FE240
HCT (%) 36.772.9 36.871.6 37.573.7 36.476.3
HGB (g/dl) 13.970.9 14.170.5 14.171.2 14.072.0
RBC (106/mm3) 6.470.5 6.470.3 6.470.7 6.371.1
WBC (103/mm3) 3.871.3 4.071.2 3.970.9 4.070.8
PLT (103/mm3) 617.4787.5 638.8769.2 600.67223.5 565.47167.0
MCV (fm3) 57.670.7 57.971.1 56.471.0 57.871.2
MCH (pg) 21.970.5 22.170.6 21.371.2 22.471.5
MCHC (g/dl) 38.170.9 38.470.7 37.872.0 38.772.3
Data are presented as mean7SD (n¼10). HCT¼Hematocrit, HGB¼Hemoglobin,
RBC¼Red blood cels, WBC¼White blood cels, PLT¼Platelet, MCV¼Mean corpus-
cular volume, MCH¼Mean corpuscular hemoglobin, MCHC¼Mean corpuscular
hemoglobin concentration.
Table 2
Relative lymphoid organs weight of rats treated daily for 28 and 90 days with C.
sylvestris hydroethanolic extract: 0 (Co), 60 (FE60),120 (FE120) and 240 (FE240) mg/
kg (mean7SD, n¼10).
28 DAYS
Lymphoid organs (g) Co FE60 FE120 FE 240
Spleen 0.2170.022 0.2170.028 0.2170.03 0.2270.025




Co FE60 FE120 FE 240
Spleen 0.1870.008 0.1970.020 0.1870.028 0.1970.020
Thymus 0.0670.008 0.0570.014 0.0570.009 0.0670.009
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within the normal ranges for Wistar rats (Bihun and Bauck, 2004;
Sharp and Regina, 1998). Furthermore, no clinical data were ob-
served to substantiate these results. In addition, one must consider
that animals treated with different doses of this plant showed no
signs of systemic toxicity, neither was affected the general welfare,
growth or normal development.In the same manner, no alterations were observed in relative
organ weight, histology of the thymus and spleen (P40.05), or in
the cellularity of the spleen and bone marrow (P40.05) (Table 5),
suggesting that this extract did not produce immunotoxic effects.4. Conclusion
In summary, these data suggest that the hydroethanolic extract
of C. sylvestris could be safe even when used over a long period.
Moreover, this study is an important contribution to the rational
use of medicinal plants on SUS. Future studies about pharmaco-
kinetics and pharmacodynamic and drug-interactions are sug-
gested for better knowledge of therapeutic safe use.
Table 3
Serum biochemical levels of rats treated daily, for 28 days, with C. sylvestris hy-
droethanolic extract: 0 (Co), 60 (FE60), 120 (FE120) and 240 (FE240) mg/kg.
Biochemistry
parameteres
Co FE60 FE120 FE 240
AST (U/L) 205.0734.1 180.5722.9 183.3720.2 205.4740.7
ALT (U/L) 48.9275.4 49.9277.4 52.0179.7 64.22735.8
GGT (U/L) 0.0670.20 0.2570.33 0.1970.30 0.3870.45
ALP (U/L) 180.1736.7 186.4725.0 216.9766.1 190.3746.5
Total protein (g/
dl)
5.9870.5 6.4070.4 7.2170.6nn 6.9470.4nn
Albumin (g/dl) 4.7170.38 4.7870.15 5.2170.29n 4.7870.21
Glucose (mg/dl) 124.8712.2 131.1712.8 129.879.8 133.2711.8
Urea (mg/dl) 50.7073.1 50.3075.0 51.1075.1 50.2075.8
Creatinin (mg/dl) 0.4970.04 0.4970.04 0.3970.04n 0.4070.03n
Uric Acid (mg/dl) 1.5470.37 1.8271.25 1.2970.43 1.5670.38
Cholesterol (mg/
dl)
37.5472.7 39.2574.4 36.417 5.5 36.7474.8
Triglycerides (mg/
dl)
192.8762.0 185.7738.2 127.3745.6nn 124.5723.0nn
Chloride (meq/L) 128.278.8 124.277.3 111.079.0nn 98.60711.2nn
Data are presented as mean7SD (n¼10). ALP, alkaline phosphatase; AST, aspartate
aminotransferase; ALT, alanine aminotransferase.
n po0.05 post test Dunn.
nn po0.01 post test Dunnett.
Table 4
Serum biochemical levels of rats treated daily for 90 days, with C. sylvestris hy-
droethanolic extract (FE): 0 (Co), 60 (FE60), 120 (FE120) and 240 (FE240) mg/kg.
Biochemistry
parameteres
Co FE60 FE120 FE 240
AST (U/L) 115.2751.2 121.7728.2 108.0721.7 116.5723.9
ALT (U/L) 55.5721.3 45.376.3 42.974.1 49.378.9
GGT (U/L) 0.770.82 0.470.52 0.570.53 0.270.42
ALP (U/L) 87.7714.4 83.278.4 99.5726.1 89.8711.9
Total Protein (g/
dl)
7.9770.52 8.0670.40 7.9170.22 8.0470.18
Albumin (g/dl) 5.3470.54 5.8070.83 5.5070.70 5.2670.38
Glucose (mg/dl) 242.5720.5 224.4721.5 229.8711.2 241.6714.2
Urea (mg/dl) 77.778.1 76.077.9 79.177.8 77.076.0
Creatinin (mg/dl) 1.2970.21 1.2170.09 1.1970.14 1.1470.04n
Uric acid (mg/dl) 1.8770.63 1.8870.54 2.1070.98 2.0570.53
Cholesterol (mg/
dl)
44.6374.1 44.1474.8 33.7573.9nn 35.6773.0nn
Triglycerides (mg/
dl)
241.6752.3 255.97110.4 265.7780.2 245.1749.9
Chloride (meq/L) 142.0716.0 143.6713.2 166.6721.1nn 154.2714.2
Data are presented as mean7SD (n¼10). ALP, alkaline phosphatase; AST, aspartate
aminotransferase; ALT, alanine aminotransferase.
n Po0.05 post test Dunn.
nn Po0.01 post test Dunnett.
Table 5
Cellularity of spleen and bone marrow of rats treated daily, for 28 and 90 days with
C. sylvestris hydroethanolic extract: 0 (Co), 60 (FE60), 120 (FE120) and 240 (FE240)
mg/kg (mean7SD, n¼10).
28 DAYS
Cellularity Co FE60 FE120 FE 240
Spleen (cellsx107) 38.0719.1 34.9717.0 32.3716.3 44.5731.9
Bone marrow (cellsx108) 16.1712.4 15.6712.9 11.977.8 12.277.4
90 DAYS
Cellularity Co FE60 FE120 FE 240
Spleen (cellsx107) 3.672.3 3.672.1 2.671.4 3.072.6
Bone marrow (cellsx108) 2.171.9 2.071.14 2.370.9 1.871.0
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